Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057244 | 0.94 | PARP1 (0.53) | PARP1CA12CA9DAOMAPT | |
| SCHEMBL2860178 | 0.81 | MAPT (0.50) | PARP1CA12CA9DAOMAPT | |
| SCHEMBL30235066 | 0.81 | MAPT (0.61) | PARP1CA12CA9MAPTHPGD | |
| SCHEMBL254651 | 0.81 | MAPT (0.61) | PARP1CA12CA9MAPTHPGD | |
| SCHEMBL11145798 | 0.78 | MAPT (0.58) | PARP1CA12CA9DAOMAPT | |
| SCHEMBL31014279 | 0.78 | MAPT (0.70) | PARP1CA12CA9DAOMAPT | |
| SCHEMBL24076903 | 0.76 | PRMT5 (0.48) | ALDH1A1 | |
| SCHEMBL895627 | 0.74 | DAO (0.73) | PARP1CA12CA9DAOMAPT | |
| SCHEMBL25746121 | 0.73 | CHEK1 (0.42) | PARP1LMNAAR | |
| SCHEMBL25430355 | 0.73 | LMNA (0.46) | PARP1DAOLMNAALDH1A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221599-A1 | PHTHALAZINONE PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN-LA ROCHE, INC. | 2009-09-03 | — | — | US | disclosed |
| US-7501410-B2 | Methods of inhibiting BTK and SYK protein kinases | ROCHE PALO ALTO LLC (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1998777-A1 | METHODS OF INHIBITING BTK AND SYK PROTEIN KINASES | F. Hoffmann-La Roche AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| EP-1999127-A1 | PHTHALAZINONE PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107469-A1 | METHODS OF INHIBITING BTK AND SYK PROTEIN KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107298-A1 | PHTHALAZINONE PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219195-A1 | e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis | ROCHE PALO ALTO LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219195-A1 | e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis | SYK, BTK, LCK | PARP1 1716/4885CA12 4804/4885CA9 4789/4885 |
| US-20090221599-A1 | PHTHALAZINONE PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | CYP3A5, CYP3A43, CYP51A1 | PARP1 1043/4885CA12 4226/4885CA9 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.